Manchester Metropolitan University

Rivus Pharmaceuticals Announces Expansion of HU6 Clinical Program and New Leadership Appointments

Retrieved on: 
Wednesday, November 15, 2023
Accounting, Obesity, Manchester Metropolitan University, Safety, A1C, SAN, Magnetic resonance imaging, Epidemiology, Nutcracker, Therapy, Phenotype, Cardiology, Cirrhosis, FACC, Risk, Vertex Pharmaceuticals, Hospital, CMA, DSM-IV codes, Patient, Diabetes, Sangamo Therapeutics, Science, Pharmacokinetics, Heart failure, Syndrome, Health, Eli Lilly, Messenger, University, Public health, Massachusetts General Hospital, Body composition, Body mass index, MASH, Type 2, Human, Type 2 diabetes, Management, Pharmaceutical industry, Lilly, Chorus

CHARLOTTESVILLE, Va. and SAN FRANCISCO, Nov. 15, 2023 /PRNewswire/ -- Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to improving metabolic health, today announced key clinical and corporate updates. The company randomized the first patient in the Phase 2b M-ACCEL trial of HU6, an investigational controlled metabolic accelerator (CMA), in obese subjects with Type 2 diabetes and at risk of metabolic dysfunction-associated steatohepatitis (MASH). Additionally, Rivus appointed Robert J. Schott, M.D., M.P.H., FACC, chief medical officer and appointed Ian F. Smith chairman of the board of directors.

Key Points: 
  • Additionally, Rivus appointed Robert J. Schott, M.D., M.P.H., FACC, chief medical officer and appointed Ian F. Smith chairman of the board of directors.
  • Approximately 280 adult patients will be randomized 2:1:2:2 into one of four treatment groups (placebo, HU6 150 mg, HU6 300 mg or HU6 450 mg) and treated for six months (26 weeks).
  • "I am delighted to be joining Rivus Pharmaceuticals, where the devoted founders and their team have made rapid progress in advancing HU6 into the clinic," said Dr. Schott.
  • "I look forward to partnering with the Rivus leadership team and other board members as we pursue the company's mission to improve human metabolic health caused by obesity.

Verastem Oncology Strengthens Executive Leadership Team with Key Appointments

Retrieved on: 
Thursday, October 26, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, Bryant University, Manchester Metropolitan University, FDA, Roivant Sciences, RAS, Strategic planning, Kite Pharma, Food, Accounting, Rare, Johns Hopkins University, Johns, PwC, Investigational New Drug, European Medicines Agency, Biologics license application, Global marketing, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Senior, Avutometinib, Celgene, Bachelor of Science, LLP, Regulation, Verastem Oncology, Assurance, Marketing, Head, Lead, Quality, Cancer, AbbVie, Patient, Consultant, MS, Regulatory affairs, Pharmaceutical industry, Management, Finance, Chemistry, Drug discovery

"These leadership appointments bring significant experience in oncology regulatory and commercial success as well as deep financial expertise as we move to the next stage of the Company’s development.

Key Points: 
  • "These leadership appointments bring significant experience in oncology regulatory and commercial success as well as deep financial expertise as we move to the next stage of the Company’s development.
  • This includes filing for accelerated approval for avutometinib and defactinib in LGSOC and preparing for a commercial launch of this potential first FDA-approved medicine for this patient population," stated Dan Paterson, President and Chief Executive Officer of Verastem Oncology.
  • "This strengthened executive team, combined with Verastem’s significant progress in advancing therapies across RAS pathway-driven cancers, is expected to accelerate our work to bring new therapies to patients with high unmet medical need."
  • Dan Calkins, Chief Financial Officer, joined Verastem Oncology in 2018 and has served as Vice President of Finance since September 2022.

Spectral AI names Prof. Paul Chadwick, Former CEO of the Royal College of Podiatry UK, as Senior Executive for UK and EMEA

Retrieved on: 
Tuesday, October 24, 2023
Knowledge, Master of Science, Birmingham City University, Smith & Nephew, Health, Spectral, MDAI, Mölnlycke Health Care, Foot, Artificial intelligence, NHS, University, Diabetes, Manchester Metropolitan University, Growth, DFU, Royal college, KOL, AI, Diabetic neuropathy, Wound healing, Nursing, Essity

“Paul brings over fifteen years of invaluable expertise in the medical devices and technology sectors to our team.

Key Points: 
  • “Paul brings over fifteen years of invaluable expertise in the medical devices and technology sectors to our team.
  • The Royal College of Podiatry is an extremely prestigious and important organization where Paul most recently served for over six years in senior executive capacities, including CEO.
  • In his previous roles at the Royal College of Podiatry, Prof. Chadwick led all the clinical, educational and financial aspects of the organization.
  • with a focus on foot ulceration from Manchester Metropolitan University and holds an undergraduate degree in Science Honors from the University of Brighton.

Stoke Therapeutics Appoints Ian Smith to its Board of Directors

Retrieved on: 
Wednesday, September 20, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Genetics, Clinical Trials, Senior advisor, Dravet syndrome, Accounting, Manchester Metropolitan University, Vertex Pharmaceuticals, Therapy, DSM-IV codes, Pharmaceutical industry, Management

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Ian Smith to its Board of Directors effective September 19.

Key Points: 
  • Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Ian Smith to its Board of Directors effective September 19.
  • “Ian brings more than two decades of significant executive management experience in the life sciences industry, with a strong track record of successfully building valuable biotech businesses,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics.
  • “I am pleased to join Stoke’s Board of Directors and look forward to working with the team to help them achieve their goals.
  • Together, I believe we have the opportunity to fundamentally change the way certain diseases are treated, starting with Dravet syndrome.”
    Ian F. Smith is a director of Stoke Therapeutics.

OMass Therapeutics Expands Leadership Team with Two New Appointments

Retrieved on: 
Wednesday, August 2, 2023
CASE, GSK, UCL, Royal college, Central nervous system, University, University of London, OSI Pharmaceuticals, Senior, Oxford, Biotechnology, Pharmacognosy, University of Cambridge, ARC, Drug, GW Pharmaceuticals, Royal London Hospital, Internal medicine, Biology, AstraZeneca, Manchester Metropolitan University, Psoriasis, Development, UCB, Shire (pharmaceutical company), Weapon Shop de Omasse, Novartis, DMPK, Toxicology, Imperial College London, MRCP, NHS, Rare, Therapy, Membership of the Royal Colleges of Physicians of the United Kingdom, Safety, Barts and The London School of Medicine and Dentistry, Management, Pharmaceutical industry, Pharmacology, Pfizer

Peter Phillips M.D., Ph.D. has joined as Senior Vice President of Clinical Development and Julia Sampson Ph.D. as Vice President of Non-clinical Development.

Key Points: 
  • Peter Phillips M.D., Ph.D. has joined as Senior Vice President of Clinical Development and Julia Sampson Ph.D. as Vice President of Non-clinical Development.
  • “Both Peter and Julia have a huge amount of experience in taking programs from preclinical through to clinical development and I am hugely excited about what they will bring to the OMass team,” said Ros Deegan, CEO of OMass Therapeutics.
  • “With our solid financial backing and new expanded facilities, we are growing our team strategically as we advance our pipeline of exciting early-stage assets in immunology and rare diseases.
  • In her most recent role at Kalvista Pharmaceuticals, she was responsible for strategy, leadership, recruitment and management of the non-clinical safety assessment team, leading toxicology, safety pharmacology and DMPK functions.

Digital Learning Institute Secures €1.8 Million in Funding and Appoints New CEO to Drive Global Expansion

Retrieved on: 
Wednesday, July 19, 2023
Workforce, Learning, UCD, Diageo, Manchester Metropolitan University, Student, BDO, DLI, Spectrum Equity, Growth, Digital, NHS, Management, Enterprise Ireland

As part of the funding round, DLI brings on board Aaron McKenna as the new CEO to spearhead growth.

Key Points: 
  • As part of the funding round, DLI brings on board Aaron McKenna as the new CEO to spearhead growth.
  • The investment follows significant growth for the company in the past two years, capturing the accelerated global transition to digital learning.
  • DLI has a vision to become the global leader in digital learning standards, with a particular focus on the US and UK markets, championing the importance of digital learning in addressing global challenges such as accessibility, inclusivity, and sustainability.
  • Under the leadership of new CEO Aaron McKenna, we are confident that DLI can go from strength to strength and expand its global footprint."

Digital Learning Institute Secures €1.8 Million in Funding and Appoints New CEO to Drive Global Expansion

Retrieved on: 
Wednesday, July 19, 2023
Workforce, Learning, UCD, Diageo, Manchester Metropolitan University, Student, BDO, DLI, Spectrum Equity, Growth, Digital, NHS, Management, Enterprise Ireland

As part of the funding round, DLI brings on board Aaron McKenna as the new CEO to spearhead growth.

Key Points: 
  • As part of the funding round, DLI brings on board Aaron McKenna as the new CEO to spearhead growth.
  • The investment follows significant growth for the company in the past two years, capturing the accelerated global transition to digital learning.
  • DLI has a vision to become the global leader in digital learning standards, with a particular focus on the US and UK markets, championing the importance of digital learning in addressing global challenges such as accessibility, inclusivity, and sustainability.
  • Under the leadership of new CEO Aaron McKenna, we are confident that DLI can go from strength to strength and expand its global footprint."

Emerging Markets PR, Marcom Firm CMW Media Announces Appointment of Cassandra Dowell to Partner, New PR Team Promotions

Retrieved on: 
Monday, July 10, 2023
Emerald, Fox News, Curaleaf, The Mercury News, B2C, Acquisition, The Wall Street Journal, USA Today, News, BFA, Roosevelt University, Manchester Metropolitan University Business School, ABC News, CNN, Partner, The New York Times, Data, Initial public offering, Cannabis, Growth, CIO, Conference, PR, Cannabidiol, Revolution, Communication, The Washington Post, Manchester Metropolitan University, Publication, SAN, Master of Science, BA, Yahoo! Finance, Lead, Communes of Burundi, Chapman University, Clothing, Farah, United Kingdom, CMW, Management, Drug, Politico, Anthropology, CBD, Journalism

SAN DIEGO, CA, July 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - CMW Media (“CMW” or the “Company”), a public relations and digital marketing agency specializing in emerging markets, announced today the appointment of Cassandra Dowell as Partner in the firm as well as the promotion of Nicole Farah to Senior Public Relations and Investor Relations Lead and Beth Adan to Senior Public Relations Account Manager on the PR team.

Key Points: 
  • “The CMW firm has a powerful story of its own, with experience educating and opening up foreign markets, and speaking at numerous educational and trade shows across the US.
  • Before joining Revolution, Dowell excelled as an award-winning journalist and cannabis trade writer based in the Chicagoland area.
  • Farah joined the CMW team as a PR Account Manager and now heads up CMW’s international operations and their growing Investor Relations team as CMW’s Senior Public Relations and Investor Relations Lead.
  • Adan is from the greater Seattle area and has a BA from Washington State University in Strategic Communications and Public Relations, alongside a BA in Anthropology.

The Inner Circle Acknowledges, Toks Adekoya as a Top Pinnacle Professional for her contributions to the field of Risk Management

Retrieved on: 
Friday, June 16, 2023
University, Federal, Delta Air Lines, SR117, Adekoya, American Express, Manchester Metropolitan University, Mentorship, UMIST, Inner circle, Certification, CHIEF, Federal Reserve, Collection, GARP, Risk management, Master, University of Manchester Institute of Science and Technology, Chemical engineering, Management, Cheminformatics, Chemistry

LIVINGSTON, N.J., June 16, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Toks Adekoya is acknowledged as a Top Pinnacle Professional for her contributions to the field of Risk Management.

Key Points: 
  • LIVINGSTON, N.J., June 16, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Toks Adekoya is acknowledged as a Top Pinnacle Professional for her contributions to the field of Risk Management.
  • Dr. Adekoya began her academic journey at The Manchester Metropolitan University where she earned a Bachelor of Science degree in Chemistry.
  • She then attended the University of Manchester Institute of Science and Technology (UMIST) where she received a Master's degree in Cheminformatics.
  • The doctor credits her success to her excellent mentors, not being scared to fail, and always doing her best.

Researchers Behind Recent Publication on SR CarnoSyn® Beta-Alanine Tablet's Ability to Improve Cognitive Health Presenting at American College of Sports Medicine and Exercise Science (ACSM) 2023 Annual Meeting

Retrieved on: 
Wednesday, May 17, 2023
Natural Alternatives International, SR, Sports medicine, Depression, Use, ACSM, Β-Alanine, Nutrient, Physiology, DRS, NAI, Research, Trial of the century, Manchester Metropolitan University, Tablet, Geriatric Depression Scale, CO, GDS, Role, American College, Conference, Medical device

Dr. Artioli has conducted and published 8 clinical studies around SR CarnoSyn® beta-alanine and carnosine health benefits.

Key Points: 
  • Dr. Artioli has conducted and published 8 clinical studies around SR CarnoSyn® beta-alanine and carnosine health benefits.
  • His beta-alanine supplementation research highlights include the positive impacts on cardio health, long term safety, and other health benefits beyond exercise physiology.
  • This clinical study was the first conducted with SR CarnoSyn® beta-alanine 600 milligram tablets, providing 2.4 grams of daily supplementation.
  • The study results indicated improved cognitive function in older adults whose cognitive function at baseline was at or below normal.